K-679: A Novel Antibody Drug-loaded Unimicelle Conjugate with Ultra-High Drug Loading Capacity Demonstrates Superior Efficacy in EGFR-Expressing Solid Tumors

K-679: A Novel Antibody Drug-loaded Unimicelle Conjugate with Ultra-High Drug Loading Capacity Demonstrates Superior Efficacy in EGFR-Expressing Solid Tumors

Kowa Company, Ltd. (Headquarters: Nagoya, Aichi Prefecture, Japan), today announced an upcoming presentation of non-clinical data for K-679, its novel antibody drug-loaded unimicelle conjugate (ADUC) with unprecedented drug loading capacity.

Kowa Company, Ltd. (headquartered in Nagoya, Aichi Prefecture, Japan), today announced the upcoming presentation of non-clinical data for K-679, its novel, antibody-loaded, unicellular conjugate (ADUC) with unprecedented drug loading capacity. The active substance, which was developed with the help of Kowa's developed micelle technology, has developed in EGFR-expressing solid tumours compared to conventional antik&